References:
1. Piscitello A, Edwards DK 5th. Estimating the screening-eligible population size, ages 45-74, at average risk to develop colorectal cancer in the United States. Cancer Prev Res (Phila). 2020;13(5):443-448.
Krist AH, Hochheimer CJ, Sabo RT, et al. Patient, Clinician, and Communication Factors Associated with Colorectal Cancer Screening. J Am Board Fam Med. 2020 Sep-Oct;33(5):779-784.
3. Lafata JE, Cooper G, Divine G, Oja-Tebbe N, Flocke SA. Patient-physician colorectal cancer screening discussion content and patients’ use of colorectal cancer screening. Patient Educ Couns. 2014;94(1):76-82.
4. Krist AH, Hochheimer CJ, Sabo RT, et al. Patient, clinician, and communication factors associated with colorectal cancer screening. J Am Board Fam Med. 2020;33(5):779-784.
5. Jones RM, Woolf SH, Cunningham TD, et al. The relative importance of patient-reported barriers to colorectal cancer screening. Am J Prev Med. 2010;38(5):499-507.
6. Zhu X, Parks PD, Weiser E, Jacobson DJ, Limburg PJ, Finney Rutten LJ. Barriers to utilization of three colorectal cancer screening options: data from a national survey. Prev Med Rep. 2021;24:101508.
7. Daly JM, Xu Y, Levy BT. Patients whose physicians recommend colonoscopy and those who follow through. J Prim Care Community Health. 2013;4(2):83-94.
8. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995.
9. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281.
10. Fendrick AM, Fisher DA, Saoud L, Ozbay AB, Karlitz JJ, Limburg PJ. Impact of patient adherence to stool-based colorectal cancer screening and colonoscopy following a positive test on clinical outcomes. Cancer Prev Res (Phila). 2021;14(9):845-850.
11. Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2022;162(1):285-299.
12. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645-1658.
13. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-1391.
14. Occult blood, fecal, immunoassay. Laboratory Corporation of America Holdings and Lexi-Comp Inc. 2021. Accessed April 11, 2022. https:// www.labcorp.com/tests/182949/occult-blood-fecal-immunoassay
15. Laboratory Corporation of America Holdings. Colon cancer screening. ColoFIT kit FAQs. Updated 2022. Accessed April 11, 2022. https://www.labcorp.com/cancer/colorectal/patients
16. Wolf MS, Baker DW, Makoul G. Physician-patient communication about colorectal cancer screening. J Gen Intern Med. 2007;22(11):1493-1499.
17. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637-1649.